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Since Weiss et al. (1951) ﬁrst reported an association between
hyperamylasemia and lung carcinoma in 1951, and Tsunashima et
al. (1976) reported amylase-producing ovarian carcinoma in 1976,
several reports of amylase-producing tumors have been documented.
Amylase is an enzyme that catalyzes the breakdown of starch, and
it is coded by two different loci: AMY1 (salivary-type) and AMY2
(pancreatic-type) localized on the short arm of the chromosome at
the 1p21 position (Zabel et al., 1983). AMY2A is a possible tumor-
suppressor gene and its deletionmay be associated with carcinogenesis
(Kang et al., 2010). Although amylase itself may not be associated with
carcinogenesis, amylase may potentially be useful as a tumor marker.
Here we report a case of amylase-producing ovarian carcinoma, and
we also conduct a retrospective study investigating the association
between hyperamylasemia and ovarian carcinoma.
Case study
In September 2011, a 49-year-old nulliparous woman was admitted
to our hospital presentingwith 1-week abdominal distension and sudden
onset epigastric pain. She hadno signiﬁcant pastmedical history. Physical
examination revealed prominent ascites and a pelvic mass. Laboratory
tests revealed slightly elevated leukocyte counts, mild liver dysfunction,
and hyperamylasemia with serum amylase of 7515 U/L (normal range
33–120) with salivary-type dominant (99%). Serum lipase was within☆ Written informed consent was obtained from the patient for publication of this case
report and accompanying images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal on request.
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day) with salivary-type dominant (88%). The amylase/creatinine clear-
ance ratio (ACCR) was 1.0 (normal range 1–5). Abdominal and pelvic
computer tomography (CT) scans exhibited a normal pancreas, ascites,
and a right adnexal tumor (10.2×6.6 cm). Pelvic magnetic resonance
imaging revealed an adnexal mass with ﬂuid-attenuated cystic and
solid components, which was suspected to be rupture of ovarian carci-
noma. Serumcarbohydrate antigen 19‐9 (CA19-9)was slightly elevated
(55.5 U/mL), while CA125 was within normal limits. She underwent
surgerywith peritonealwashing cytology, total abdominal hysterectomy,
bilateral salpingo-oophorectomy, and omentectomy. After detailed and
careful discussion, she refused lymphadenectomy based on her concerns
about complications such as lymphedema. Serous ascites and minor
rupture of the right adnexal mass were observed. Tumor metastasis to
adjacent organs was not noted, but peritoneal washing cytology was
positive for atypical cells with large nuclei. Histology of the right ovary
showed serous adenocarcinoma (high grade, pT1c) without evidence of
metastasis (Fig. 1A). Immunohistochemically, cytoplasmic staining for
amylase was more apparent, compared with negative control (Fig. 1B,
C). Based on the FIGO criteria of ovarian carcinoma, she was diagnosed
as having serous adenocarcinoma with FIGO stage Ic disease. Within
24 h after surgery, this patient's serum and urine amylase returned to
normal. She received 6 cycles of combination chemotherapy at the
following doses: docetaxel (70 mg/m2 iv) and carboplatin (AUC 5).
Her last follow-up was April 2012, and there was no sign of recurrence.
Materials and methods
This retrospective study was approved by the institutional review
board of our hospital. Written informed consent was obtained from
all patients. Data on women undergoing salpingo-oophorectomy
from 2007 to 2011was evaluated. All patients were ethnically Japanese.
Patients with endometrial cystic lesions were excluded from the study.
To avoid confounding macroamylasemia, patients with renal failure
were excluded. We stratiﬁed the women into two groups: group 1
with ovarian malignancy and group 2 with benign ovarian tumors. All
serum amylase, CA19-9, and CA125 levels were measured prior to
surgery. Hyperamylasemia is deﬁned as serum amylase >2 standard
deviation (SD) above the upper range of normal. We assessed the in-
cidence of hyperamylasemia and correlation between amylase and
CA19-9/CA125.
Results were analyzed by JMP (version 10, SAS institute, Tokyo,
Japan). Differences in categorical variables were assessed by Fisher's
exact test or chi-square test. Differences in continuous variables
were analyzed using the Student's t test or one-way ANOVA. The
Fig. 1. Histology of the right ovary showing serous adenocarcinoma. A. Hematoxylin
and eosin stain, 200× magniﬁcation. B. Immunohistochemical staining for salivary-type
amylase, 200× magniﬁcation. C. Negative control of immunohistochemical staining for
salivary-type amylase, 200× magniﬁcation.
Fig. 2. Serum amylase level. Malignant = ovarian carcinoma (group 1), benign= benign
ovarian tumor (group 2), serous = serous adenocarcinoma, others = ovarian carcinoma
except for serous adenocarcinoma, dotted line = upper normal range of serum amylase,
solid line = median of serum level of each group.
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CA19-9/CA125 in patientswith ovarian carcinoma. Descriptive statistics
were used and presented as mean, SD, and frequency. Multivariate
logistic regression was used to explore the relationships between
malignancy and hyperamylasemia; the results of the analysis were
expressed as an odds ratio (OR) with 95% conﬁdence interval (CI).
Pb0.05 was considered statistically signiﬁcant.
Results
Group 1 consisted of 70women aged 20–87with ovarian carcinoma.
Group 2 consisted of 158 women aged 20–89 with benign ovarian
tumors. Thewomen in group 1were older than those in group 2 (55±14
vs 44±16; Pb0.001). Group 1 included serous adenocarcinoma (29/70)and other carcinomas (41/70) (S1). Fig. 2 indicates the distribution of
serum amylase levels. There was no signiﬁcant difference in serum amy-
lase levels between group 1 and group 2 (199 U/L±891 U/L, median
68.5 U/L vs 83 U/L±76 U/L, median 73 U/L; P=0.11). However, group
1 had a signiﬁcantly higher incidence of hyperamylasemia (15/70,
21.4%), compared with group 2 (10/158, 6.3%) (sensitivity 21.4%; speci-
ﬁcity 93.5%; OR, 4.03; 95% CI, 1.71–9.52; Pb0.002). After adjusting for
age, the ORwas 3.48 (95% CI, 1.43–8.74; Pb0.0059). Patients with serous
carcinoma had a signiﬁcantly higher incidence of hyperamylasemia
(11/29, 38%) compared with other carcinomas (4/41, 9.8%) and benign
tumors (10/158, 6.3%) (Pb0.001). After adjusting for age and stage,
there was also a signiﬁcant difference between serous adenocarcinoma
and other carcinomas (P=0.01). Serum amylase level was signiﬁcantly
higher in patients with serous adenocarcinoma (382 U/L±1376 U/L,
median 86 U/L) than patients with other ovarian carcinoma (69 U/L±
37 U/L, median 63 U/L) and benign tumor (83 U/L±76 U/L, median
73 U/L) (Pb0.01). Fig. 3 displays the correlations between amylase and
CA19-9/CA125 in patients with ovarian carcinoma. CA19-9 showed a
negative correlation with amylase (Spearman r=−0.35, Pb0.005).
There was no demonstrable correlation between amylase and CA125
(Spearman r=−0.007, P=0.96).
Discussion
Amylase is mainly produced by pancreatic and salivary gland tissues,
but the AMY1 andAMY2 genes are also expressed in lung, trachea, ovary,
fallopian tubes, and uterine cervix (Seyama et al., 1994). It is also a
well-known nonspeciﬁc marker for pancreatitis. As this patient had
epigastric pain and hyperamylasemia, acute pancreatitis was initially
suspected. However, salivary-type amylase was dominant, and lipase,
which is more speciﬁc to the pancreas, was normal. Abdominal and
pelvic CT scans detected a pelvic mass and ascites, and not pancrea-
titis. Hyperamylasemia, normal ACCR, and serous adenocarcinoma
immunohistochemically positive for amylase conﬁrmed the diagnosis
of amylase-producing ovarian carcinoma. This entity sometimesmimics
pancreatitis.
Few studies have investigated the association between hyper-
amylasemia and ovarian carcinoma. Zakrezewska and Pietrynczak
(1996) reported that 39% of patientswith ovarian carcinomahad hyper-
amylasemia, with salivary-type dominant. They also found that amylase
was signiﬁcantly elevated in women with ovarian carcinoma. However,
their study did not assess age differences. Ueda et al. (1994) reported
that serum amylase increaseswith age. Agewas probably a confounding
Fig. 3. Correlation between serum amylase and CA19-9/CA125 level in patients with ovarian carcinoma.
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high.
The sensitivity of serum amylase was rather lowwith 79.6% ovarian
carcinoma patients having a normal amylase and the benign tumor
group having higher median amylase levels than those patients with
ovarian carcinoma. However, the speciﬁcity of serum amylase was
very high, with 93.5% of ovarian carcinoma patients exhibiting elevated
serum amylase levels.
Many well-known tumor markers such as CA125 and CA19-9 are
sensitive, but not speciﬁc. Therefore, amylase, particularly in conjunc-
tion with existing markers may represent a promising tumor marker
(Zakrezewska & Pietrynczak, 1996). This may be especially true for
serous adenocarcinomawith signiﬁcantly higher serum amylase levels.
It is interesting that serum amylase in ovarian carcinoma negatively
correlates with serum CA19-9. The pathophysiology of this is not
clear, but serum amylase may represent a potential tumor marker in
CA19-9 negative patients.
Themechanismof this high amylase level is still unclear. Sayama et al.
(1994) reported that the AMY1 gene (salivary-type)was exclusively and
highly expressed in the salivary glands and in amylase-producing lung
adenocarcinomas. It is also reported that AMY2A (pancreatic-type)
may be associated with carcinogenesis (Kang et al., 2010; Watanabe et
al., 2010). Neoplastic transformation of cells may result in expression of
AMY1 gene and biosynthesis of salivary-type amylase.
There are several limitations to our study. First, group 1 included
women with various stages of carcinoma (S1). To assess the level of
serum amylase according to the stage, we need larger study groups.
Other limitations are retrospective design and short observational period.
We need longer observation if we assess serum amylase as a possible
marker for recurrence. At this time, we can only say that serum amylase
is a possible diagnostic marker.
In conclusion, amylase-producing tumors sometimes mimic pancrea-
titis. Since hyperamylasemia is common in ovarian carcinoma, we
should be aware of the possibility that patients with hyperamylasemia
(especially salivary-type) may have ovarian carcinoma after excluding
other common etiologies. Hyperamylasemia may be associated withovarian carcinoma, and measurement of serum amylase in conjunction
with existing tumor makers may represent a more speciﬁc screening
regimen.
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